Author

Mariyana Eneva

Observed names: M I Eneva, M. Eneva, Mariyana I. Eneva

Institution: Medical University of Sofia

Observed institutions: Bulgarian National Bank, Medical University of Sofia

ORCID: 0009-0007-7853-9793

Observed ORCID: 0009-0007-7853-9793

OpenAlex ID: A5045033727

Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer

2020 · Mila P. Petrova, Mariyana I. Eneva, et al. · BioScience Trends · 61

Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer

2020 · M P Petrova, I S Donev, et al. · Clinical & Experimental Immunology · 39

Prevalence and prognosis of PIK3CA mutations in Bulgarian patients with metastatic breast cancer receiving endocrine therapy in first‐line setting

2023 · R. Gencheva, M. Petrova, et al. · Cancer Reports · 3

Tumor neutrophil extracellular traps and pretreatment neutrophils in association with progression-free survival in patients with metastatic non-small cell lung cancer receiving pembrolizumab alone or with chemotherapy.

2022 · Mila Petrova, Dimiter Parvanov, et al. · Journal of Clinical Oncology · 1

Impact of structured oncologist-led home visits on psychological distress and resilience in patients with solid tumors undergoing chemotherapy: A comparative study.

2026 · Sonya Kircheva Draganova, Radostina Gencheva, et al. · Journal of Clinical Oncology

Effectiveness of ribociclib in metastatic breast cancer in one hospital in Bulgaria—results from real-world clinical practice

2026 · Mariyana Eneva, Petya Borisova, et al. · Pharmacia

The clinical pharmacist’s role in optimising the management of menopausal symptoms in breast cancer survivors: a narrative review

2026 · Mariyana Eneva, Manoela Manova · Pharmacia

Effect of a single home visit on distress in cancer patients undergoing chemotherapy: A comparative study.

2025 · Mila Petrova, Sonya Kircheva Draganova, et al. · Journal of Clinical Oncology

PI3KCA mutation prevalence and outcome among patients with metastatic breast cancer in Bulgaria treated with first-line endocrine therapy.

2023 · Radostina Gencheva, Savina Hadjidekova, et al. · Journal of Clinical Oncology

1318P Neutrophil extracellular traps as a potential predictive marker for treatment with pembrolizumab alone or with chemotherapy as a first-line in patients with metastatic non-small cell lung cancer

2021 · M. Petrova, D. Parvanov, et al. · Annals of Oncology

High neutrophil to lymphocyte ratio as a predictor for hyperprogressive disease in patients with metastatic non-small cell lung cancer treated with pembrolizumab as a second line.

2020 · Milla Petrova, Mariyana Eneva, et al. · Journal of Clinical Oncology

Works count: 11

Citation count: 104

H-index: 3

I10-index: 2